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Background: The emergence of artemisinin-resistant Plasmodium falciparum parasites in Southeast Asia threatens
global malaria control efforts. One strategy to counter this problem is a subsidy of malaria rapid diagnostic tests
(RDTs) and artemisinin-based combination therapy (ACT) within the informal private sector, where the majority of
malaria care in Myanmar is provided. A study in Myanmar evaluated the effectiveness of financial incentives vs
information, education and counselling (IEC) in driving the proper use of subsidized malaria RDTs among informal
private providers. This cost-effectiveness analysis compares intervention options.
Methods: A decision tree was constructed in a spreadsheet to estimate the incremental cost-effectiveness ratios
(ICERs) among four strategies: no intervention, simple subsidy, subsidy with financial incentives, and subsidy with
IEC. Model inputs included programmatic costs (in dollars), malaria epidemiology and observed study outcomes.
Data sources included expenditure records, study data and scientific literature. Model outcomes included the
proportion of properly and improperly treated individuals with and without P. falciparum malaria, and associated
disability-adjusted life years (DALYs). Results are reported as ICERs in US dollars per DALY averted. One-way
sensitivity analysis assessed how outcomes depend on uncertainty in inputs.
Results: ICERs from the least to most expensive intervention are: $1,169/DALY averted for simple subsidy vs no
intervention, $185/DALY averted for subsidy with financial incentives vs simple subsidy, and $200/DALY averted for
a subsidy with IEC vs subsidy with financial incentives. Due to decreasing ICERs, each strategy was also compared
to no intervention. The subsidy with IEC was the most favourable, costing $639/DALY averted compared with no
intervention. One-way sensitivity analysis shows that ICERs are most affected by programme costs, RDT uptake,
treatment-seeking behaviour, and the prevalence and virulence of non-malarial fevers. In conclusion, private
provider subsidies with IEC or a combination of IEC and financial incentives may be a good investment for
malaria control.
Keywords: Cost-effectiveness, Malaria, Rapid diagnostic test, Artemisinin combination therapy, Subsidy, Behaviour
communication change, Drug resistance, Informal provider, MyanmarBackground
Artemisinin resistance threatens worldwide efforts to
control and eliminate malaria. Artemisinin is the most
effective first-line anti-malarial against Plasmodium fal-
ciparum parasites, and the first signs of drug resistance
were seen in Cambodia since 2006 [1,2]. By 2012, arte-
misinin resistance was seen in the Thai-Myanmar border* Correspondence: Ingrid.chen@ucsf.edu
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unless otherwise stated.area [3]. This finding is a call for action, as it is reminis-
cent of the worldwide spread of chloroquine resistance
[4,5]. In order to ensure that the front-line anti-malarial
remains efficacious for the 216 million individuals infected
with malaria throughout the world each year, aggressive
efforts to curb artemisinin resistance are critical [6].
An estimated 37.4 million people in Myanmar live in
malaria-endemic areas, where 74% of malaria cases are
P. falciparum infections and 26% are Plasmodium vivax
infections [7]. Malaria is prevalent year-round and the
risk of infection is mostly in rural, forested areas athis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Chen et al. Malaria Journal  (2015) 14:55 Page 2 of 12altitudes of less than 1,000 m [7,8]. There is a wide range
of uncertainty in the incidence of malaria in Myanmar,
as the large number of cases from migrants working in
forests and agricultural areas are difficult to quantify.
Recent estimates of the number of cases range between
500,000 cases (in 2011) to 4.2 million cases (in 2008),
resulting in 9,100 deaths annually [9-11].
In Myanmar, a combination of unregulated drugs and
their overuse due to symptomatic diagnosis are major
sources of pressure on drug resistance [7,12]. Drug resist-
ance may be selected when parasites survive exposure to
low levels of drugs [13], which in Myanmar is encouraged
by counterfeit drugs that contain sub-therapeutic doses
of artemisinin monotherapy [14-17], and providers that
prescribe artemisinin monotherapy, especially at lower
doses than recommended to cure malaria [18]. Both of
these practices are common in the largely unregulated
private sector, where 40-80% of the population seeks
health care [7,12].
Within the Myanmar informal private sector, common
practices of itinerant drug vendors and pharmacists
include the overuse of artemisinin-family compounds
through symptomatic diagnosis and their misuse through
the sale of artemisinin monotherapy [7]. These practices
are a result of the prohibitively high costs of malaria rapid
diagnostic tests (RDTs) and artemisinin-based combin-
ation therapy (ACT), which includes a long-acting anti-
malarial to lessen the selective pressure for artemisinin
drug resistance. The targeting of donor funds for RDTs
and ACT in the private sector therefore offers the poten-
tial to drive the proper use of artemisinin-based drugs in
Myanmar.
The subsidy of ACT and RDTs for use in the private
sector is expected to be the most important intervention
to prevent the spread of drug resistance in Myanmar
[18]. As RDTs do not require specialized training or
equipment, the provision of subsidized RDTs with a
training session can improve diagnostic accuracy [19].
Also, subsidized ACT is quality controlled and if sold at
lower prices than other anti-malarials, can replace
artemisinin monotherapy.
Although ACT subsidies in Africa and Asia are in-
creasing in number, to date only Cambodia has deployed
both RDTs and ACT to the private sector at a national
scale [20]. The Cambodia programme, which started in
2002, showed that RDT uptake was slow, reaching the
highest levels seven years after the intervention was in-
troduced, although there was no data on the quality of
RDTs or provider adherence to test results [20]. The
Cambodian experience suggested that future RDT sub-
sidies to informal providers should include a training
programme emphasizing the importance of RDTs and
their proper use, and that financial incentives could also
be explored to promote RDT uptake [20]. A recent pilotstudy was conducted in rural Myanmar that builds on
these suggestions, in addition to incorporating commu-
nity education to drive consumer demand for RDTs. The
pilot study also explored the use of information, educa-
tion and counselling (IEC) sessions to encourage RDT
use among informal private providers.
The exploration of financial incentives vs IEC for sub-
sidized malaria RDT use in the informal private sector is
novel, and the World Health Organization (WHO) rec-
ommends that the cost-effectiveness of new interven-
tions be established before strategies are recommended
as policy [18]. The objective of this study is to assess the
cost-effectiveness of three subsidy strategies: a simple
subsidy, subsidy with financial incentives and subsidy
with IEC, to drive the appropriate use of malaria RDTs
among informal private providers in Myanmar.
Methods
Model overview
The cost-effectiveness for a RDT subsidy scheme pilot
study was estimated using a decision tree model con-
structed in a spreadsheet (Excel, Microsoft 2010). The
decision tree compared three intervention arms with ‘no
intervention’ (Figure 1), considering programme and
medical costs from a societal perspective. The decision
tree comprises of a decision node among the subsidy ap-
proaches, followed by chance nodes based on the true
disease status, followed by test and treatment conse-
quences. The model estimates the health and economic
value of each outcome (detailed in Additional file 1).
Costs included programmatic costs (overhead, staff,
travel, and supply costs) and patient commodity costs,
and were based on Population Services International
(PSI) Myanmar’s finance and account records. Cost re-
cords comprised of PSI overhead costs scaled to the
pilot study, actual pilot study costs, staffing costs from
the artemisinin monotherapy replacement (AMTR)
programme (scaled to the number of outlets reached by
the pilot study), as well as commodity costs from other
programmes (detailed in Additional file 1). The ex-
change rate used was 907 Kyat/USD, from 1 May, 2013.
Effectiveness was estimated in disability-adjusted life
years (DALYs), based on the health effects of malaria
and non-malarial fevers and appropriateness of the
medicine prescribed. DALYs resulting from death were
calculated based on the years lost from mortality, based
on the difference between mean life expectancy and
average age of malaria deaths, with a 3% discount rate
applied to each year in the future. DALYs for surviving
patients were calculated by multiplying the average dur-
ation of illness with the disability weight for the illness,
based on published disability levels [21,22] (detailed in
Additional file 1). For every path of events in the deci-
sion tree, the associated health outcomes were weighted
Figure 1 Decision tree model for malaria rapid diagnostic test subsidy schemes.
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of the weighted health outcomes.
Cost-effectiveness was measured incrementally, as the
cost per DALY averted for the study population, the
number of patients that seek private provider care at all
outlets enrolled in the RDT pilot study from May to
September, 2013. ICERs showed that adding programmes
led to increased costs that were compensated by large in-
creases in effectiveness. Due to this scenario, which is
called ‘extended dominance’, the cost-effectiveness of each
option was also compared with no intervention (further
detail on extended dominance available in Additional
file 1). Model assumptions are described in Additional
file 1, and do not account for onward malaria transmission
(from untreated cases) or the possibility of selection for
drug resistance.Programme description
The pilot study took place in the Mon and Shan states
in rural Myanmar. The study recruited approximately
600 private providers between April and September
2013. Three types of private providers were recruited:
providers in general retail stores, itinerant drug vendors
and medical drug representatives. All providers had been
receiving subsidized ACT since September 2012 through
PSI Myanmar’s AMTR programme, which aims to crowdout artemisinin monotherapy with subsidized quality-
assured ACT.
Townships were selected on the basis of similar popu-
lation size, malaria burden and socio-economic charac-
teristics, and intervention arms were randomized at a
township level. The three pilot study arms were:
 Arm 1: simple subsidy of RDTs for sale at 100 Kyat
(approximately $0.12) to retailers with a support
visit every month
 Arm 2: RDT subsidy with financial incentive: one
free RDT for every five purchased with a support
visit every month
 Arm 3: RDT subsidy with support visits every two
weeks.
Prior to RDT rollout, community sensitization activ-
ities were also performed in all pilot study locations.
Data input values
For data inputs (Tables 1, 2 and 3), each study arm was nor-
malized to target 600 outlets. Data inputs employed a com-
bination of finance/account records and management
information systems (MIS) data from PSI Myanmar, quanti-
tative and qualitative data from the pilot study, and a review
of published scientific literature (detailed in Additional
file 1). RDT uptake and the treatment prescribed were
Table 1 Base case data inputs for epidemiology, health outcomes and diagnostic test characteristics
Parameter Input value Source
Epidemiology
Percentage of P. falciparum (P.f.)/P. vivax
(P.v.) malaria
65% P.f./35% P.v. Published data [23], PSI Myanmar
stock audit data
Proportion of febrile cases in population
that are malaria
8% PSI Myanmar MIS data (Sun Primary Health)
Average number of febrile patients that
visit one private provider per month
20 PSI Myanmar MIS data (Sun Primary Health)
Health outcomes
Case fatality rates for P. falciparum
malaria
Given ACT 0.01% Very low probability
Given chloroquine or quinine 0.7% Published data on falciparum drug
resistance [24]
Given no anti-malarial 3% Published case fatality rates in Bago [25]
and on eastern border of Myanmar [26]
Case fatality rates for P. vivax Given ACT 0.01% Very low probability
Given chloroquine or quinine 0.01% Published P. vivax treatment rates with
chloroquine in Papua [27]
Given no anti-malarial 1% Extrapolated from published materials from
Papua [28]
Case fatality rate for non-malarial
febrile illnesses
Given ACT or other anti-malarial 0.2% Published data from Bago, Myanmar [25]
triangulated with PSI MIS data
Given no anti-malarial 0.16% Published data on burden of disease in
Myanmar [29] and non-malarial fevers in
Laos [30]
Average duration of malaria illness without
effective treatment
1 week Published data on hospital records
in Myanmar [31]
Average duration of non-malarial febrile illness 1 week Assumption
DALY weight of malaria 0.2 Published data [21]
DALY weight of non-malarial fever 0.18 Estimated from published data [22]
Mean life expectancy in Myanmar 62 years Average from 3 studies [32-34]
Average age of malaria-induced death in
intervention townships
25 years PSI Myanmar MIS data
Average age of non-malarial febrile death
in Myanmar
30 years PSI Myanmar MIS data
Discount rate 3% Standard rate
Diagnostic test characteristics
RDT sensitivity and specificity P. falciparum sensitivity 100% Published RDT performance [35]
P. falciparum specificity 97% Published RDT performance [35]
Pan plasmodium sensitivity 92% Published RDT performance [35]
Pan plasmodium specificity 98% Published RDT performance [35]
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four analytical methods: 1) household surveys, 2) inter-
views with private providers, 3) mystery client visits,
and 4) stock audit data from supply points. The house-
hold surveys measured RDT uptake at a community/
patient level before and after the intervention. The in-
terviews with private providers included a survey of
anti-malarial and RDT stock and prices. RDT uptake
was also measured through mystery clients, who pre-
sented with an alleged fever to enrolled providers in thebeginning and end of the pilot study. Stock audit data
monitored RDT and ACT use, including RDT results
which the programme required be written on the RDT,
and returned to supply points for resupply. The literature
search comprised of a series of Web of Knowledge and
Google Scholar searches conducted between November
2012 and April 2013. Keywords included malaria,
Myanmar, drug adherence, artemisinin, and subsidy;
all references were screened for potential relevance to
this study.
Table 2 Base case inputs for provider behaviour*
Provider behaviour No intervention Arm 1 Arm 2 Arm 3
Probability of clinical diagnosis 0.98 0.98 0.98 0.92
Probability of using RDT 0.02 0.02 0.02 0.08
Diagnosis Medicine prescribed
Clinical Diagnosis ACT 0.05 0.12 0.12 0.19
Other anti-malarial 0.03 0.07 0.07 0.07
No anti-malarial 0.92 0.81 0.81 0.74
RDT Pan + falciparum + ACT 0.75 0.78 0.84 0.87
Other anti-malarial 0.05 0.05 0.05 0.05
No anti-malarial 0.2 0.17 0.11 0.08
RDT Pan + falciparum - ACT 0.5 0.10 0.10 0.10
Other anti-malarial 0.25 0.45 0.45 0.45
No anti-malarial 0.25 0.45 0.45 0.45
RDT Pan - falciparum + ACT 0.75 0.78 0.84 0.87
Other anti-malarial 0.05 0.05 0.05 0.05
No anti-malarial 0.2 0.17 0.11 0.08
RDT Pan - falciparum - ACT 0.4 0.057 0.083 0.022
Other anti-malarial 0.02 0.029 0.056 0.089
No anti-malarial 0.58 0.914 0.861 0.889
*Source: pilot study data from household survey, mystery client visits, provider demographics from in-depth qualitative interviews, and PSI Myanmar MIS data.
‘No antimalarial’ comprises of the use of antipyretics 70% of the time and antibiotics 30% of the time, as described and rationalized in the Additional File
section ‘Assumptions’.
Note: baseline RDT uptake is a conservative lower bound based on household surveys with denominator adjusted to only include care sought from informal
providers. Mystery clients were prompted to suggest they have malaria, possibly motivating providers to use RDTs at higher rates than in real-life scenarios.
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One-way sensitivity analysis was performed on each in-
put value, and results were ranked as inputs that most
affect costs, and inputs that most affect health outcomes.
Base case results represent a lower bound estimate for
RDT uptake, and the rationale for the sensitivity analysis
ranges explored are detailed in Additional file 1. The
ICERs were calculated and ranked, and significant in-
puts, defined as affecting an absolute change in cost by
more than $14,400 ($100 per 1,000 individuals annually),
and/or an absolute change in more than 3,600 DALYs
(25 DALYs per 1,000 individuals annually) across the
study population, were reported.
Ethical considerations
In 2012, the Myanmar Ministry of Health ceded author-
ity to the AMTR project, which includes the RDT pilot
study, to PSI Myanmar. The RDT pilot study received
approval from the PSI Research Ethics Board (REB). The
members of the study team from the University of
California, San Francisco did not interact with patients.
Results
Costs
The costs are divided into commodities, programme ex-
penses (mainly staff ), time, and travel (Table 4 showsyear 1, subsequent years detailed in Additional file 1). Pro-
grammatic expenses were the main expense, comprising
of over half of the costs for each study arm (Figure 2). For
the total study population (144,000 individuals annually;
600 providers * 20 febrile patients per provider monthly *
12 months/year), a simple subsidy was also the least ex-
pensive ($625,486, $4,300 per 1,000 individuals annu-
ally), with the addition of financial incentives requiring
minor increases in price ($626,342, $4,350 per 1,000 in-
dividuals annually), and the incorporation of IEC re-
quiring further expenses ($734,339, $5,100 per 1,000
individuals annually).
The RDT donor costs reflect a $0.36 subsidy per unit
from the donor for arms 1 and 3, and a $0.48 subsidy per
unit for arm 2. These are scaled to a base case uptake of 2%
for arms 1 and 2, and 8% for arm 3 (Table 2). Total com-
modity costs include all patient purchases: $0.32 per RDT,
$0.53 per subsidized ACT (donor costs not included in ana-
lysis), $0.55 per course of ‘other anti-malarial’ (quinine or
chloroquine), and $0.58 per course of ‘no anti-malarial’
(weighted as 70% antipyretic/30% antibiotic). The donor
RDTcost is also specified for programmatic planning.
Health outcomes
Health outcomes are reported as DALYs (Table 5). A sim-
ple subsidy offered reasonable improvements compared to
Table 3 Costs for rapid diagnostic test intervention
Annual direct programme first year costs (non-recurrent in italics)
Costs for RDT intervention, 600 providers No intervention Arm 1 Arm 2 Arm 3
Interpersonal communicators $0 $34,599 $34,599 $34,599
Jr Health Service Officers $0 $17,568 $17,568 $17,568
Product promoters $0 $31,374 $31,374 $62,748
Office personnel $0 $79,186 $79,186 $79,186
Incentives for providers $0 $17,784 $17,784 $17,784
Commodities $95,614 $103,658 $104,087 $119,127
Materials for providers $0 $19,656 $19,656 $19,656
Materials for product promoters $0 $324 $324 $324
Field staff training $6,951 $6,951 $6,951
Field staff transport: monthly office visits $0 $30,834 $30,834 $53,028
Motorcycle taxi $0 $39,202 $39,202 $59,402
PSI Overhead $0 $5,329 $5,329 $5,329
Shipping logistics $0 $1,271 $1,271 $1,271
Total, year 1 $95,614 $387,735 $388,163 $476,973
Non-recurrent, year 1 $0 $59,334 $59,334 $59,334
Recurrent annual $95,614 $328,401 $328,829 $417,639
Commodity cost per unit
No intervention Arm 1 Arm 2 Arm 3
RDT societal cost (donor + patient) $1.16 $0.68 $0.80 $0.68
ACT $1.65 $1.65 $1.65 $1.65
Quinine and chloroquine $0.55 $0.55 $0.55 $0.55
‘No anti-malarial’ (70% antipyretics, 30% antibiotics) $0.58 $0.58 $0.58 $0.58
Patient and provider time and travel costs
Costs for RDT intervention, 600 providers No intervention Arm 1 Arm 2 Arm 3
Patient and provider time costs $0 $53,366 $53,366 $64,498
Provider travel costs to restock RDTs $0 $79,344 $79,344 $79,344
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DALYs averted per 1,000 individuals annually). The finan-
cial incentive led to a very minor improvement of only 5
DALYs averted compared to a simple subsidy (0.035
DALYs averted per 1,000 individuals annually). The most
substantial improvement was provided by the IEC strategy,
providing 540 DALYs averted (536 due to deaths averted,
four due to morbidity averted) compared to the subsidyTable 4 Annual commodities, programmatic expenses, time a
Scenario (societal) Total cost Drug and RDT cos
Total (R
No intervention $96,996 $95,614 $0
Arm 1: simple subsidy $625,486 $103,658 $1
Arm 2: subsidy with financial incentive $626,342 $104,087 $1
Arm 3: subsidy with IEC $734,339 $119,127 $4
*Includes time spent conducting RDT, and provider time for monthly supply point v
**Patient travel costs were excluded and were the same across each arm, estimated
Bold = donor costs.with financial incentive. This translates to 3.75 DALYs
averted per 1,000 individuals annually. A simple RDT sub-
sidy, therefore, improved health outcomes, with effects fur-
ther enhanced through an IEC strategy.
Incremental cost-effectiveness ratios
The base case ICERs for year one are: $1,169/DALY
averted for the simple RDT subsidy compared to nond travel cost











,037 $387,735 $54,748 $79,344
,382 $388,163 $54,748 $79,344
,147 $476,973 $58,896 $79,344
isit based on wages, as providers were not compensated by the programme.
to be $504,000 per arm.
Figure 2 Categorized societal costs (annual).
Figure 3 Cost and DALYs averted vs no intervention.
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financial incentives compared to simple subsidy, and
$200/DALY averted for subsidy with IEC compared to
subsidy with financial incentive (Table 5 shows year 1,
subsequent years are shown in Additional file 1).
Since the ICER decreases from the first comparison
(simple subsidy vs no intervention, $1,169/DALY) to the
second comparison (subsidy with incentives vs simple
subsidy, $185/DALY), representing extended dominance,
study arms were also compared directly with no inter-
vention (Table 5). The result was $1,169/DALY averted
for a simple subsidy, $1,159/DALY averted for a subsidy
with financial incentives, and $639/DALY averted for a
subsidy with IEC. The costs and health benefits of the
simple subsidy proved to be very similar to the subsidy
with financial incentives, while IEC showed increases in
cost offset by large improvements in health outcomes
(Figure 3).
Sensitivity analysis
One-way sensitivity analysis shows that the analysis is
driven by the levels of RDT uptake, levels of treatment-
seeking within outlets, programmatic costs, drug costs,
the prevalence and virulence of non-malarial fevers, and
the virulence of P. falciparum malaria (Table 6, de-
scribed below and detailed in Additional file 1).
RDT uptake was the most significant driver of costs and
DALYs. By increasing RDT uptake in each study arm from
0 to 0.65 (the highest level found in mystery client sur-
veys), health outcomes improved significantly, and costsTable 5 Cost-effectiveness ratios from a societal perspective f




No intervention $96,996 – 10,155
Arm 1: Simple subsidy $625,486 $528,490 9,703
Arm 2: Subsidy with
financial incentive
$626,342 $857 9,698
Arm 3: Subsidy with IEC $734,339 $107,997 9,158increased as a result of RDT use. The number of patients
reached by the intervention also drove costs and health
outcomes; enrollment of busy outlets receiving 40 febrile
patients per month were more cost-effective than outlets
seeing one febrile patient per month.
The main drivers of cost alone were programmatic
staff costs and drug commodity costs. The main drivers
of health outcomes alone were more diverse. Primarily,
health outcomes were driven by the virulence and preva-
lence of febrile illnesses, shown by immense health con-
sequences when case fatality rates of non-malarial fevers
were increased (from a probability of 0.001 to 0.05). The
fact that P. falciparum malaria was the most virulent
cause of fever was also significant; while only 8% of fe-
vers were malaria, in the absence of an RDT, health out-
comes were better with higher rates (50% vs 3%) of
presumptive treatment of fevers as malaria. Health bene-
fits of the intervention were also proportional to malaria
endemicity, shown by increasing the prevalence of mal-
aria from 3% to 20% among febrile cases.
Discussion
This study is the first cost-effectiveness analysis to exam-
ine behaviour change communication and incentive strat-
egies for malaria, providing a randomized comparison of
different subsidy methods with high-quality cost data. The
study found that IEC was a cost-effective and promising
strategy to encourage the uptake of subsidized RDTs in
the Myanmar informal private sector. This strategy pays
off with an attractive ICER of $200 per DALY averted asor first year of intervention
LYs DALYs averted vs
prior strategy
Incremental cost









Table 6 One-way sensitivity analysis summary for year 1 costs*
Parameter Value (Low, high
of range)
Order** ICERs ($/DALY averted)
Low, high of range
2nd vs 1st 3rd vs 2nd 4th vs 3rd
Inputs that affect costs and
health outcomes
Base case N/A C, 1, 2, 3 $1,169 $185 $200
Probability of using RDT
in arm 1 (base case 0.02)
0.00 C, 1, 2, 3 $1,389 $53 $200
0.65 C, 2, 1, 3 1,159 $45 Dominated (DOM)
Probability of using RDT
in arm 2 (base case 0.02)
0.00 C, 2, 1, 3 $1,390 $39 $200
0.65 C, 1, 3, 2 $1,169 $3 $2
Probability of using RDT in arm 3
(base case 0.08)
0.02 C, 1, 2, 3 $1,169 $185 $317
0.65 C, 1, 2, 3 $1,169 $185 $72
Number of febrile patients seeking
care per private sector provider
per month (base case 40)
1 C, 1, 2, 3 $23,046 $1,939 $3,323
40 C, 1, 2, 3 $594 $139 $118
Probability of ‘no anti-malarial’
administration for clinical diagnosis,
arm 1 (base case 0.81)**
0.5 C, 2, 1, 3 $1,159 $34 DOM
0.93 C, 1, 2, 3 DOM $1,159 $200
Probability of ‘no anti-malarial’
administration for clinical diagnosis,
arm 2 (base case 0.81)***
0.5 C, 1, 2, 3 $1,169 $35 DOM
0.93 C, 2, 1, 3 DOM $1,169 $200
Probability of ‘no anti-malarial’ administration
for clinical diagnosis, arm 3 (base case 0.74)***
0.5 C, 1, 2, 3 $1,169 $185 $93
0.93 C, 1, 2, 3 $1,169 $185 DOM
Probability of ACT administration for clinical
diagnosis, no intervention (base case 0.05)***
0.05 C, 1, 2, 3 $1,169 $185 $200
0.4 C, 1, 2, 3 DOM $200 $200
Inputs that affect costs only
Programme costs per febrile individual
(base case $0 for C, $3.61 for arms 1
and 2, and $4.23 for arm 3)
$2 C, 1, 2, 3 $655 $92 $36
$10 C, 1, 2, 3 $3,204 $92 $36
Cost of ‘no anti-malarial’ (base case $0.58) $0.30 C, 1, 2, 3 $1,178 $194 $205
$1.00 C, 1, 2, 3 $1,156 $272 $193
Cost of ACT, same across all arms (base case $1.65) $0.50 C, 2, 1, 3 $1,148 $179 $99
$2.50 C, 1, 2, 3 $1,186 $199 $214
Probability of using RDT for no intervention
(base case 0.02)
0.02 C, 1, 2, 3 $1,169 $185 $200
0.11 C, 1, 2, 3 $4,183 $185 $200
Cost of other anti-malarial, same across all
arms (base case $0.55)
$0.18 C, 1, 2, 3 $1,165 $179 $200
$1.65 C, 1, 2, 3 $1,183 $201 $201
Inputs that affect health outcomes only
Probability of death for non-malarial
fever given no anti-malarial (base case 0.0016)
0.001 C, 1, 2, 3 $1,873 $297 $247
0.05 C, 1, 2, 3 $37 $6 $12
Probability of death for non-malarial
fever given ACT (base case 0.002)
0.001 C, 1, 2, 3 $846 $140 $153
0.05 C, 1, 2, 3 DOM DOM DOM
Percentage of febrile illnesses that
are malaria (base case 8%)
3% C, 1, 2, 3 $7,825 $1,363 $787
20% C, 1, 2, 3 $384 $60 $72
Probability of death for non-malarial
fever given other anti-malarial (base case 0.002)
0.001 C, 1, 2, 3 $940 $141 $198
0.05 C, 1, 2, 3 DOM DOM DOM
Discount rate (base case 3%) 0% C, 1, 2, 3 $673 $106 $117
5% C, 1, 2, 3 $1,592 $253 $269
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Table 6 One-way sensitivity analysis summary for year 1 costs* (Continued)
Probability of death for P. falciparum malaria
given no anti-malarial (base case 0.03)
0.005 C, 1, 2, 3 DOM DOM $9.960
0.04 C, 1, 2, 3 $829 $128 $149
Life expectancy in Myanmar (base case 62) 50 C, 1, 2, 3 $1,475 $234 $252
80 C, 1, 2, 3 $974 $153 $166
*Year 1 costs are sufficient to describe the relative differences between the arms, which do not change in subsequent years. Results are based on cut-offs: 25
DALYs and/or $100 per 1,000 individuals. Italics = inputs that affect the order of ICERs.
**Order of ICERs based on cost, from least to most expensive. C = no intervention. 1 = arm 1, 2 = arm 2, 3 = arm 3, skipping over DOM (dominant). ***Holding
other anti-malarial constant.
Chen et al. Malaria Journal  (2015) 14:55 Page 9 of 12compared to subsidy with financial incentive alone (or
$639 per DALY averted compared to no intervention). At
base case, IEC led to four times the RDT uptake as com-
pared to a simple subsidy (arm 1) or a subsidy with finan-
cial incentives (arm 2).
The financial incentive of offering providers one free
RDT for every five RDTs purchased showed marginal
improvements to a simple subsidy, with similar total
costs. This strategy was therefore also cost-effective, with
an ICER of $185 per DALY averted compared to a sim-
ple subsidy (or $1,159 per DALY averted compared to
no intervention) although the quality of care was not as
high as that which resulted from the IEC strategy. It is
possible that the financial incentive used in this inter-
vention may not be as influential as a direct cash incen-
tive; in-depth interviews with providers revealed that the
financial incentive did not motivate RDT use, and fur-
thermore, that behaviours were mainly driven by altru-
ism (MS, pers comm.). This finding may explain the
success of the IEC strategy although other PSI interven-
tions have suggested that providers receiving direct cash
incentives were over-incentivized (PSI Myanmar staff, un-
published observations). The types of financial incentives
for RDT use could, therefore, use further exploration.
Sensitivity analysis revealed three main drivers of inter-
vention outcomes. Cost and effectiveness were driven by
the number of patients that seek health care from enrolled
private providers, showing the importance of targeting in-
formal providers, the main first point of care among rural
populations in Myanmar [7,12]. Costs were driven by pro-
grammatic and commodity costs, suggesting that subsidies
are necessary to overcome the prohibitively high cost of
malaria RDTs and ACT in the informal private sector.
Health outcomes were contingent on the prevalence of
non-malarial fevers and their virulence depending on
treatment given, showing the importance of a confirmed
non-malaria diagnosis.
Since this pilot study is meant to inform the nation-
wide scale-up of RDTs in Myanmar, its implications
should be tailored accordingly. While costs can be pre-
dicted linearly for scale-up, programme effectiveness is
much more complex. Efforts should be focused to en-
sure that drivers of programme effectiveness, as identi-
fied through sensitivity analysis, are optimized. As themain determinant of effectiveness was RDT uptake,
monitoring and evaluation of provider adherence to the
programme will be critical during scale-up. To ensure
the availability of RDTs for uptake, a steady supply chain
of RDTs and ACT is also essential. Programme effective-
ness also depends on the number of patients reached, so
busy outlets that do not enroll in the RDT subsidy
scheme must be identified and targeted. Strategies to
incentivize their enrollment must then be explored. Fi-
nally, the impact of this intervention is driven by the
pre-eminence of the informal private sector as a point of
care for fever. Care-seeking behaviour in Myanmar must
continually be monitored, and in case of change, inter-
ventions will need to be redirected.
The findings in this study cannot be directly compared
to other reported studies, as the cost-effectiveness of be-
haviour change strategies for malaria is novel. However,
the implications of this study are consistent with those
found in many other studies. A cost-effectiveness ana-
lysis comparing RDTs to microscopy or presumptive
treatment found that in sub-Saharan Africa, RDTs were
the most cost-effective strategy, an effect that increased
with decreasing malaria prevalence [36]. In the present
study, RDTs were also more cost-effective than pre-
sumptive diagnosis, yet cost-effectiveness was seen to in-
crease with malaria endemicity. This was a result of high
fixed programmatic costs, unaffected by growing malaria
endemicity, despite increasing DALYs incurred and
averted in each study arm.
In Africa, a few studies have explored the impact of
providing RDT subsidies to informal providers, support-
ing that IEC strategies may be necessary to drive proper
RDT use, which cannot be achieved by financial incen-
tives alone. In western Kenya, despite improved RDT
uptake following a simple subsidy (of 85 to 100% price
reduction to the patient), the intervention was not cost-
effective due to poor provider compliance to negative
test results, as well as high malaria endemicity in the re-
gion (Cohen, unpublished observations). In Uganda, in-
formal providers were trained to use subsidized RDTs,
resulting in high levels of programme compliance and
adherence to test results [37]. The present study has
similar findings with regard to the importance of edu-
cational interventions to supplement RDT subsidies.
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communication strategies are context specific, and that
results of this study should only be applied to Myanmar.
In Myanmar, a few RDT and ACT subsidies have also
been reported, showing similar implications to the study
herein. A programme in 2005 entailed the provision of
free RDTs and ACT to Myanmar midwives, successfully
decreasing the use of artesunate monotherapy [25], and
a study in 2009 showed that volunteers could be trained
to use RDTs to improve malaria treatment practices
[38]. A cost study on malaria treatment from 2004,
which quantified patient costs for treatment-seeking
within the informal private sector, found that the average
malaria patient in rural Myanmar spent an equivalent of
4.2 days of per capita economic output (approximately
$3.50) travelling to informal providers [39]. These high
patient travel costs have an important implication to the
present study, which excluded patient travel costs that
would otherwise amount to $504,000 per arm annually.
As patient travel costs in rural Myanmar are high, subsi-
dized services and care should certainly be provided to
alleviate total costs to the patient.
Limitations
There are key limitations to this analysis. While the
model is useful for the prediction of programmatic costs,
it does not account for ongoing malaria transmission or
the spread of drug resistance. Due to these limitations,
there are two additional factors that must be considered
for intervention scale-up. The first is coverage, as
difficult-to-reach border areas with Thailand are at high-
est risk for artemisinin resistance [40], with agricultural
migrants being the highest risk populations [41,42].
Extra care must be taken to ensure high coverage of pro-
viders in these areas, and to develop strategies to target
high risk, hard-to-reach individuals [26,43]. The second
factor is the sensitivity of RDTs, which limits this inter-
vention to identification of clinical symptomatic cases of
malaria only. The elimination of asymptomatic carriers,
which have recently been implicated as a potentially im-
portant source of transmission of P. falciparum malaria
[44], may therefore require additional strategies and
approaches.
Future directions
As malaria endemicity drops, it is critical to ensure that
interventions keep up to date with changing epidemi-
ology [45]. At the time of the study, only 8% of fevers in
pilot study townships were due to malaria. In light of
these declining rates, there are two areas of future re-
search that must be addressed. The first is a need for a
quantitative assessment of non-malarial fevers in
Myanmar, and the second is to garner surveillance data
from used RDTs.A recent quantification of causes of fever in Laos,
where P. falciparum endemicity is also declining [30],
provides a valuable example Myanmar to follow. More
importantly however, is a global need for strategies to
manage non-malarial fevers within the informal private
sector, as current practices entail the widespread use of
antibiotics, threatening drug resistance [46].
The large-scale subsidy of RDTs in Myanmar also pro-
vides a potential reservoir of malaria surveillance data.
Since malaria cases become clustered in low-endemic
settings [44], positive RDT results should be reported to
rapidly detect and eliminate pockets of infection. Dried
blood spots from used RDTs can also be further analysed
for molecular surveillance, as parasite DNA has shown
to be easily extracted from used RDTs [47]. This can be
used to detect asymptomatic carriers, and to provide
insight on RDT sensitivity and quality [47].Conclusion
In the global fight against artemisinin resistance, the
proper case management of malaria in Myanmar is
critical. Malaria diagnostic and treatment practices in
Myanmar can be improved by targeting subsidized RDTs
and ACT to informal private providers. IEC offers a
cost-effective strategy to motivate the effective use of
RDTs, with further benefits offered by the addition of
financial incentives to an IEC strategy, with minimal
increases in cost.Additional file
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